Crucially, the authors found that mutations in chromatin regulators like NSD1 were enriched in the Immunity-H group and positively correlated with enhanced immune signatures, suggesting that alterations in NSD-family genes may promote anti-tumor immune activity. Here, SLC17A5 is linked to neoplasm.